BindingDB logo
myBDB logout

25 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
22496391 40 Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.EBI Bristol-Myers Squibb Research
22930276 25 Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors.EBI Amgen, Inc
23371965 1 The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.EBI University of Michigan Medical School
22613176 1 Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen.EBI Pacific University Oregon
25415535 118 Inhibitors of c-Jun N-terminal kinases: an update.EBI Eberhard Karls Universit£t T£bingen
25441013 49 Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.EBI Vertex Pharmaceuticals Inc
24694071 11 New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.EBI MicuRx Pharmaceuticals Inc.
23896611 16 Tetrazole-based deoxyamodiaquines: synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.EBI University of Cape Town
23810496 31 Synthesis and biological evaluation of aminobenzimidazole derivatives with a phenylcyclohexyl acetic acid group as anti-obesity and anti-diabetic agents.EBI Korea Research Institute of Chemical Technology
16248836 154 Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.EBI F. Hoffmann-La Roche Ltd.
22784008 100 Synthesis and biological evaluation of the 1-arylpyrazole class ofs(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).EBI Esteve
22708876 106 Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.EBI Merck Research Laboratories
22239545 287 Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19.EBI Amgen Inc.
18345609 57 Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration.EBI The Institute of Cancer Research
17630726 32 Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.EBI Novartis Institutes for BioMedical Research
15634016 232 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6.EBI Human BioMolecular Research Institute
21978946 45 Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.EBI Takeda Pharmaceutical Company, Ltd.
21411321 28 Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.EBI Merck Research Laboratories
19810674 93 Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate (NW-1772) as a highly potent, selective, reversible, and orally active monoamine oxidase B EBI Universita degli Studi di Bari
17399990 45 In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).EBI Université Laval